Publications by authors named "Rashida Z Mustafa"
Article Synopsis
- Ibrutinib, a treatment for chronic lymphocytic leukemia (CLL), causes a rapid increase in blood lymphocytes, mainly due to CLL cells moving from lymphoid tissues into the bloodstream.
- In a clinical trial, patients taking ibrutinib showed a significant reduction in CLL cell adhesion to fibronectin within days, while the effect on migration to other signals was less pronounced.
- The study suggests that inhibiting specific adhesion pathways (BTK and VLA-4) may lead to a better understanding of how ibrutinib induces lymphocytosis and potentially weakens CLL cell survival signals in their environment.
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental factors for proliferation and survival. In particular, tissue-resident CLL cells show prominent activation of both B-cell receptor (BCR) and NF-κB pathways. We evaluated the in vivo effects of ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor on tumor cell activation and proliferation in the blood, lymph node, and bone marrow of patients with CLL.
View Article and Find Full Text PDF